Fusion Antibodies (LON:FAB) Trading Down 0.8% – What’s Next?

Fusion Antibodies plc (LON:FAB) dropped 0.8% during trading on Tuesday . The stock traded as low as GBX 14.50 and last traded at GBX 14.64. Approximately 375,892 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 616,346 shares. The stock had previously closed at GBX 14.75.

Fusion Antibodies Stock Performance

The stock’s fifty day simple moving average is GBX 14.06 and its 200-day simple moving average is GBX 13.52. The company has a quick ratio of 2.36, a current ratio of 3.87 and a debt-to-equity ratio of 2.40. The company has a market capitalization of £16.63 million, a PE ratio of -9.76 and a beta of 0.49.

Fusion Antibodies (LON:FAB) last released its quarterly earnings data on Monday, November 24th. The company reported GBX (0.50) earnings per share for the quarter. Fusion Antibodies had a negative net margin of 195.95% and a negative return on equity of 137.11%. On average, research analysts predict that Fusion Antibodies plc will post -129.9999875 earnings per share for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.